8 completed. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 3 | Completed 3 |
Follow Recurrent Osteosarcoma: new trials by email Literature Review of Recurrent Osteosarcoma trials Research Report on Recurrent Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-06-05 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors tanespimycin, pharmacological study, laboratory biomarker analysis - Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 70 | 2004-09-01 | 2013-06-04 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 95 | 2004-02-01 | 2013-06-05 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas alvocidib, pharmacological study - Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2001-04-01 | 2013-07-02 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma tanespimycin, pharmacological study - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 1999-10-01 | 2013-02-07 |
Osteosarcoma (8) · Neuroectodermal Tumors, Primitive, Peripheral (6) · Neuroblastoma (5) · Astrocytoma (3) · Burkitt Lymphoma (3) · Familial ependymoma (3) · Medulloblastoma (3) · Chondrosarcoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Desmoplastic Small Round Cell Tumor (2) · Hodgkin Disease (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Melanoma (2) · Optic Nerve Glioma (2)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Bone Tissue (8) · Neoplasms, Connective Tissue (8) · Neoplasms, Connective and Soft Tissue (8) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Nerve Tissue (7) · Neoplasms, Neuroepithelial (7) · Neuroectodermal Tumors (7) · Neuroectodermal Tumors, Primitive (7) · Sarcoma (6) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5)
tanespimycin (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · CTLA-4 Antigen (1) · Erlotinib Hydrochloride (1) · HhAntag691 (1) · Ipilimumab (1) · Irinotecan (1) · Nivolumab (1) · Oxaliplatin (1) · Temozolomide (1) · alvocidib (1) · pepinemab (1)
National Cancer Institute (NCI) (7) · Children's Oncology Group (1)
United States (8) · Canada (1)
Crystal L Mackall (1) · Emily G Greengard (1) · James Whitlock (1) · Lisa McGregor (1) · Mrinal Gounder (1) · Ramesh Ramanathan (1) · Regina Jakacki (1) · Tanya Trippett (1)
PMID 31401903, PMID 32192573, PMID 38520670
U01CA097452 (3), U01CA069856 (2), UM1CA097452 (2), N01CM62206 (1), P30CA008748 (1), U01CA099168 (1)